hotspot -WSS

hotspot

author：knowledge 2025-09-30 16:29:16 - browse：695

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Dramatically reducing cancer deaths requires the PASTEUR Act

explore

focus

WSS

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

What Mike Pence has said that could be used in a Donald Trump trial

ER docs worry over extreme heat as a 'mass casualty event'

For BCIs, commercial hurdles may be bigger than scientific ones

In venture capital firm's success, lessons for turning crisis into profit

entertainment

hotspot

explore

Heart attack and stroke risk calculators need revising

Verily hires former Apple Health leader as chief scientific officer

Medical leaders decry Supreme Court decision on affirmative action

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Supreme Court strikes down use of affirmative action

The painfully weak evidence on taking collagen to treat arthritis

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Influencer to be charged after chaos erupts in New York City's Union Square

Activists slam private health insurers over coverage restrictions

What the cancer research community can learn from the Covid response

explore

For BCIs, commercial hurdles may be bigger than scientific ones

Ohioans vote in high

Travel bans should be based on evidence, not politics or fear

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Attacks on the drug industry will lead to fewer breakthroughs

Discs beat pads, tampons for heavy menstrual flow, new study shows

explore

focus

hotspot

hotspot